Zealand Pharma Forecast, price target & analysts
Zealand Pharma Target price 2026 - Analyst rating & recommendation
Zealand Pharma Classifications & Recommendation
Zealand Pharma Price Target
| Target Price | kr428.40 |
| Price | kr275.90 |
| Potential |
55.27%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Zealand Pharma 2027 .
The average Zealand Pharma target price is kr428.40.
This is
55.27%
register free of charge
kr787.50
185.43%
register free of charge
kr303.00
9.82%
register free of charge
|
|
| A rating was issued by 25 analysts: 14 Analysts recommend Zealand Pharma to buy, 10 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Zealand Pharma stock has an average upside potential 2027 of
55.27%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion kr | 9.21 | 4.83 |
| 14,599.09% | 47.61% | |
| EBITDA Margin | 77.49% | 40.02% |
| 103.91% | 48.36% | |
| Net Margin | 70.05% | 39.55% |
| 104.07% | 43.54% |
19 Analysts have issued a sales forecast Zealand Pharma 2026 . The average Zealand Pharma sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Zealand Pharma EBITDA forecast 2026. The average Zealand Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Zealand Pharma Analysts have issued a net profit forecast 2026. The average Zealand Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share kr | 91.56 | 27.57 |
| 663.79% | 69.89% | |
| P/E | 10.01 | |
| EV/Sales | 1.24 |
17 Analysts have issued a Zealand Pharma forecast for earnings per share. The average Zealand Pharma EPS is
This results in the following potential growth metrics and future valuations:
Current Zealand Pharma Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BNP PARIBAS |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Aug 26 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Aug 19 2026 |
| WELLS FARGO SECURITIES, LLC |
Locked
➜
Locked
|
Locked | Aug 16 2026 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | Jun 10 2026 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | Jun 09 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BNP PARIBAS:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Aug 26 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Aug 19 2026 |
|
Locked
WELLS FARGO SECURITIES, LLC:
Locked
➜
Locked
|
Aug 16 2026 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
Jun 10 2026 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
Jun 09 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
